• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Revelyst Announces Chief Supply Chain Officer

    4/23/24 7:00:00 AM ET
    $BDX
    $EMBC
    $VSTO
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer.

    Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply chain, sourcing and logistics leader is key to helping Revelyst and its brands begin this new chapter.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423438660/en/

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Beck most recently served as Vice President of Global Supply Chain for embecta (NASDAQ:EMBC), a medical technology company where he oversaw global supply chain and distribution operations, including the overhaul of their global network design, planning, logistics, and trade technology and change management leadership. Beck was part of embecta's leadership team executing the separation from Becton Dickinson and Co. (NYSE:BDX). During the transition, he helped establish the company's supply chain infrastructure while ensuring continuity of supply and mitigating customer disruptions. His ability to design and deploy global supply chain operations for a standalone business — including hiring talent, building effective teams and developing processes, analytics and technology — made him an ideal candidate to be Revelyst's first Chief Supply Chain Officer.

    "Bringing a change agent like Joe to Revelyst's leadership team is critical for our goal of becoming the industry's No. 1 house of brands," said Eric Nyman, CEO of Revelyst. "He has a unique talent for transforming a company's supply chain by consolidating facilities and building new capabilities, which have a direct impact on the bottom line. Joe will help revolutionize Revelyst at the enterprise, platform and brand level, and we welcome his innovative thinking as we continue to build our culture of empowerment and excellence."

    Before embecta, Beck worked for Medtronic and UPS, two global Fortune 500 companies where he streamlined and optimized supply chain operations, which he will replicate and enhance in this new role. Beck is the latest executive to join Revelyst's growing management team, including Nyman, CFO Andy Keegan, General Counsel Jung Choi and CHRO Joyce Butler. The addition of Beck will provide Revelyst with the supply chain and sourcing savvy needed in an increasingly competitive and complex global economy.

    "This is the opportunity of a lifetime because it combines my outdoor passions with my love of helping companies become more efficient and effective moving products and information across the global supply chain," said Beck. "I look forward to building a world-class team whose sole focus is optimizing the way Revelyst does business, building scale across our portfolio and developing innovative strategies that give our company and our brands a significant competitive advantage to accelerate growth."

    About Revelyst

    Revelyst, a segment of Vista Outdoor Inc. (NYSE:VSTO), is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240423438660/en/

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX
    $EMBC
    $VSTO

    CompanyDatePrice TargetRatingAnalyst
    Embecta Corp.
    $EMBC
    5/6/2026Buy → Neutral
    BTIG Research
    Becton Dickinson and Company
    $BDX
    5/4/2026$180.00Outperform
    Evercore ISI
    Becton Dickinson and Company
    $BDX
    4/10/2026$167.00Neutral
    Goldman
    Becton Dickinson and Company
    $BDX
    2/10/2026$202.00Overweight
    Barclays
    Becton Dickinson and Company
    $BDX
    2/3/2026$233.00Buy
    Citigroup
    Becton Dickinson and Company
    $BDX
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    Becton Dickinson and Company
    $BDX
    5/22/2025$185.00Buy → Neutral
    Citigroup
    Becton Dickinson and Company
    $BDX
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $BDX
    $EMBC
    $VSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/3/26 12:44:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    VP, Chief Accounting Officer Roth Anthony M. was granted 30,000 shares, increasing direct ownership by 61% to 78,833 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    6/2/26 5:02:51 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/2/26 2:11:50 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Embecta Corp. downgraded by BTIG Research

    BTIG Research downgraded Embecta Corp. from Buy to Neutral

    5/6/26 7:32:56 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Evercore ISI resumed coverage on Becton Dickinson with a new price target

    Evercore ISI resumed coverage of Becton Dickinson with a rating of Outperform and set a new price target of $180.00

    5/4/26 8:48:11 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Becton Dickinson with a new price target

    Goldman resumed coverage of Becton Dickinson with a rating of Neutral and set a new price target of $167.00

    4/10/26 12:23:31 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $BDX
    $EMBC
    $VSTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BDX
    $EMBC
    $VSTO
    SEC Filings

    View All

    $BDX
    $EMBC
    $VSTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    embecta to Participate in Investor Events

    PARSIPPANY, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2026 Jefferies Global Healthcare Conference Management will host one-on-one investor meetings on Wednesday, June 3, 2026, at the Marriott Marquis, New York City. TD Cowen Diabetes Tech Summit Management will host a fireside session on Friday, June 5, 2026, at 9:40 a.m. CT / 10:40 a.m. ET, at the Westin New Orleans, LA. 2026 Goldman Sachs 47th Annual Global Healthcare Conference Managemen

    6/1/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

    New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures.FRANKLIN LAKES, N.J., May 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams. Designed to enhance efficiency, versatility, and procedural workflow across urologic stone management and soft tissue procedures, the innovative new system supports consistent performance in demanding clinical enviro

    5/21/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Peter Menziuso Named EVP and President, BD Interventional

    FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a $5 billion global business with responsibility for commercial opera

    5/18/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    5/29/26 8:39:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    5/27/26 11:25:39 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Becton Dickinson and Company

    SD - BECTON DICKINSON & CO (0000010795) (Filer)

    5/22/26 1:24:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Vitor Roque Chief Financial Officer

    FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio

    5/7/26 6:31:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Financials

    Live finance-specific insights

    View All

    BD Reports Second Quarter Fiscal 2026 Financial Results

    Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXNGAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectivelyExecuted a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarterCompany reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026. "We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen,

    5/7/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported second quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed second quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, May 5, 2026, which is accessible here, or access the teleconference here. The live webcast can also be accessed via the company'

    5/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 15, 2026 to stockholders of record at the close of business on May 28, 2026.About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channel

    5/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    12/2/24 4:30:15 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    11/27/24 12:42:04 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care